The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...

Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") .  Such investors are advised to contact Danielle Peyton at ...

Nektar Therapeutics said that a phase 1 study examining a combination of NKTR-255 in combination with an autologous ...

Itovebi is supplied as a tablet in 2 dosage strengths: 3 mg and 9 mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens. The FDA has ...

Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...

Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

Asking physicians how they perform less-invasive surgeries for breast cancer can help reassure patients that their lymphedema ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...

Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...